Ceapro Inc. develops, manufactures and markets a range of plant-derived specialty ingredients intended for use in the nutraceutical, pharmaceutical, personal care and animal health sectors. The company’s core product lines include natural saponin extracts sourced from quillaja bark, betulinic acid and betulin purified from birch bark, and microencapsulated beta-glucans derived from barley. These ingredients are used for their immune-modulating, anti-inflammatory and skin-conditioning properties, and are supplied to ingredient distributors, contract manufacturers and branded finished-goods companies.
Headquartered in Edmonton, Alberta, Ceapro operates a research and manufacturing facility that integrates extraction, purification and microencapsulation technologies under one roof. The company leverages proprietary processing techniques to enhance bioavailability and stability of its active compounds, enabling customers to formulate dietary supplements, functional foods, beverages, topical skincare products and veterinary formulations.
Founded in the early 1990s, Ceapro has evolved from a small extract manufacturer into a science-driven biotech company with a global customer base. Its international distribution network spans North America, Europe and select Asian markets, where it partners with co-manufacturers and contract research organizations to support product development and regulatory compliance.
Ceapro’s research efforts are guided by a leadership team with expertise in bioprocess engineering, analytical chemistry and regulatory affairs. The company continues to invest in clinical and preclinical studies to substantiate the health benefits of its key active ingredients and to expand its pipeline of plant-based innovations.
AI Generated. May Contain Errors.
Free CRPOF Stock Alerts